Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Mar 15;5(5):1116-7.
doi: 10.18632/oncotarget.1835.

Dopamine signaling: target in glioblastoma

Jiri Bartek  1 , Zdenek Hodny
Affiliations
Comment

Dopamine signaling: target in glioblastoma

Jiri Bartek et al. Oncotarget. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Targeting synergistic dependency on MAPK and dopamine signaling in glioblastoma
Canonical pro-survival and mitogenic MAPK signaling, commonly deregulated in glioblastoma, is depicted as a simplified signaling cascade of EGFR, Ras-GTP and MAPK kinases Erk1 and Erk2 (Erk1/2). At the Ras node, MAPK pathway is positively modulated by dopamine signaling. Upon ligand binding, the DRD2 receptor holds inactive small GTPase Rap1 through activation of heterotrimeric G protein alpha i2 (alpha/beta/gamma) and the GTPase-activating protein RAP (RAP-GAPII), which promote GDP-bound (inactive) Rap1. Rap1 is a Ras antagonist and its inactivation thus results in amplification of MAPK signaling. Therefore, combined targeting of both pathways can offer a promising strategy for glioblastoma therapy.
See this image and copyright information in PMC

Comment on

References

    1. Li J, et al. Oncotarget. 2014;5(this issue)
    1. Stork PJ, Dillon TJ. Blood. 2005;106:2952–61. - PMC - PubMed
    1. Bartek J, Jr, et al. J Neurol Neurosurg Psychiatry. 2012;83:753–60. - PubMed
    1. Nature. 2008;455:1061–8. - PMC - PubMed
    1. De Witt Hamer PC. Neuro Oncol. 2010;12:304–16. - PMC - PubMed